Clinical trials
Lung Cancer (Locally Advanced or Metastatic) clinical trials
Below are recruiting lung cancer (locally advanced or metastatic) clinical trials, each written for real people, not researchers. We’re tracking 5,800 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07445048RecruitingPhase 3
Radiation, targeted therapy, and immunotherapy for high-risk head and neck cancer
This trial tests if adding a targeted drug (nimotuzumab) and an immunotherapy (benmelstobart) after surgery and radiation can help prevent cancer from returning in patients with high-risk head and neck cancer who cannot take cisplatin chemotherapy.
ShanghaiAges 18 years+ - NCT07446855RecruitingPhase 1/Phase 2
Study of AZD4956 for advanced solid tumors with DNA repair problems
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
New York, New YorkAges 18–130 - NCT07450859RecruitingPhase 2
Study of new drug for metastatic pancreatic cancer
This trial tests a new drug called nuzefatide pevedotin for people with metastatic pancreatic cancer that has progressed after one prior treatment. The drug targets a protein called EphA2 found on some tumor cells and may slow tumor growth.
Phoenix, ArizonaAges 18 years+ - NCT07437898RecruitingPhase 2
Adebrelimab plus chemo before surgery for esophageal cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
Putian, FujianAges 18–75 - NCT07444645Recruiting
New delivery method for liver cancer radiation therapy
This trial tests a special catheter (TriNav) to deliver radiation directly to liver tumors. It aims to improve targeting and reduce side effects for people with liver cancer that cannot be surgically removed.
Houston, TexasAges 18 years+ - NCT07438626RecruitingPhase 2
Sacituzumab tirumotecan for SMARCB1-deficient kidney cancer
This trial tests an investigational drug called sacituzumab tirumotecan for a rare and aggressive type of kidney cancer called renal medullary carcinoma (RMC) or a related variant. The drug is designed to target and deliver treatment directly to cancer cells. The study aims to see if it can shrink tumors or slow the disease in people who have already tried other treatments.
Houston, TexasAges 18 years+ - NCT07439120RecruitingEarly Phase 1
Testing a new radioactive drug for advanced solid tumors
This trial tests a new radioactive drug called 68Ga/177Lu-BRP-020063 in people with advanced solid tumors, especially bladder or breast cancer. The drug seeks out Nectin-4 on cancer cells, helping doctors see and potentially treat the tumors. The goal is to check that the drug is safe and tolerable.
ShanghaiAges 18 years+ - NCT05472259RecruitingPhase 2
Testing two chemotherapy combos for metastatic pancreatic cancer
This Phase 2 study compares two chemotherapy combinations to treat metastatic pancreatic cancer that has progressed after gemcitabine (with or without Abraxane). It aims to see which combination works better and is tolerable for people with measurable disease.
Antwerp, AntwerpAges 18 years+ - NCT06786026RecruitingPhase 2
Drug combo plus chemotherapy for first-line advanced triple-negative breast cancer
This trial tests whether adding an experimental immunotherapy drug (QL1706) with or without bevacizumab to standard chemotherapy can help people with advanced triple-negative breast cancer that hasn't been treated yet. It aims to improve outcomes for patients who have already had earlier treatment but whose cancer has come back or spread.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07427992Recruiting
Study of zolbetuximab for stomach cancer with claudin 18.2
This trial is looking at a drug called zolbetuximab, given with chemotherapy, for people with a certain type of stomach or gastroesophageal junction cancer that has spread and has high levels of a protein called claudin 18.2. The goal is to see how well it works in real-world settings.
MilanAges 18–100 - NCT07434843RecruitingPhase 2
Pemigatinib for a rare type of GIST
This trial tests a drug called pemigatinib for people with a specific type of GIST (SDH-deficient GIST) that has spread or cannot be removed with surgery. The goal is to see if the drug can help stop the cancer from growing.
Boston, MassachusettsAges 18 years+ - NCT07426250Recruiting
Blood test to guide treatment for limited cancer spread
This trial looks at using a simple blood test (ctDNA) to help guide treatment for people whose cancer has spread to a few places. It may help doctors choose the best local treatment and monitor how well it works.
Aarhus NAges 18 years+ - NCT07426809Recruiting
A study to improve lumpectomy surgery with real-time imaging
This study tests a new imaging tool that helps surgeons see cancer margins in real time during a lumpectomy, aiming to reduce the need for a second surgery. It is for women with early-stage breast cancer who are planning a lumpectomy.
Beaumont, DublinAges 18 years+ - NCT07426835Recruiting
Comparing two hernia prevention methods in robotic esophageal cancer surgery
This trial compares two ways of closing the diaphragm during robotic esophageal cancer surgery to see if one reduces the chance of a hernia later. If you're having a robotic esophagectomy for cure, you may be able to join.
Dublin, BeaumontAges 18 years+ - NCT07417189RecruitingPhase 1/Phase 2
Study of ABSK141 for advanced solid tumors with KRAS G12D mutation
This study tests a new drug called ABSK141 for people with advanced solid tumors that have a specific mutation called KRAS G12D. It aims to see if the drug can shrink or control the cancer, and it has different phases for different groups of patients.
ShanghaiAges 18 years+ - NCT04423185RecruitingPhase 2
Precision medicine trial for rare advanced solid tumors
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
BeijingAges 18 years+ - NCT07419490Recruiting
Moving ovaries and uterus to preserve fertility during pelvic radiation
This trial moves the ovaries and uterus higher in the belly before pelvic radiation to protect them, so patients may still be able to have children later. It is for women aged 18-40 with pelvic cancers that require radiation.
Tampa, FloridaAges 1.5 years–3.3 years - NCT07419464RecruitingPhase 2
Testing 5-FU for head and neck cancer that has returned
This trial tests the drug 5-fluorouracil (5-FU) in people with head and neck cancer that has come back or spread. It aims to see if 5-FU can help when other treatments have stopped working.
St Louis, MissouriAges 18 years+ - NCT07422753RecruitingPhase 2
TACE with immunotherapy drugs for advanced liver cancer
This trial tests a combination of TACE (a procedure that blocks blood supply to the tumor) plus three immunotherapy drugs (sintilimab, bevacizumab, ipilimumab) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination works better than TACE alone.
Hangzhou, ZhejiangAges 18–75 - NCT07417501RecruitingPhase 2
Lenvatinib plus immunotherapy for advanced cancers with 11q13 amplification
This trial tests a combination of two drugs, lenvatinib (a targeted therapy that stops blood vessel growth to tumors) and a PD-1 inhibitor (an immunotherapy that helps your immune system fight cancer), in people with advanced solid tumors that have a specific genetic change called 11q13 amplification. The goal is to see if this combination can shrink or control tumors that haven't responded to other treatments.
Wuhan, HubeiAges 18 years+ - NCT04458792Recruiting
Builds a cancer blood-and-biomarker database after sarcoma treatment
This study collects information and blood samples from adults with sarcoma who had surgery and possibly radiation. The goal is to build a large dataset that helps researchers understand sarcoma better and improve future care.
Montpellier, HeraultAges 18 years+ - NCT06337942Recruiting
Bladder or kidney-bladder transplant from a deceased donor
This trial offers a first-in-human transplant of a bladder or a kidney combined with a bladder from a deceased donor. It is for people with severe bladder problems or bladder cancer who already need a new bladder or are on immune-suppressing medicines for a prior organ transplant.
Los Angeles, CaliforniaAges 18–70 - NCT06644716Recruiting
FAPI PET-CT scan to find unknown primary cancer
This study tests a new type of PET-CT scan using a tracer called FAPI to find the original source of cancer when standard tests have not been able to. It may help identify the primary tumor in people with cancer that has spread from an unknown location.
AmsterdamAges 18–99 - NCT07412314Recruiting
Proton Therapy for Recurrent Nasopharyngeal Cancer
This trial uses proton therapy (a precise type of radiation) to treat people whose nasopharyngeal cancer has come back. It aims to see if this treatment can help control the cancer while limiting side effects.
Guangzhou, GuangdongAges 18 years+
Hear when a new Lung Cancer (Locally Advanced or Metastatic) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (locally advanced or metastatic)?
- Yes. Clin2 currently lists 5,800 recruiting lung cancer (locally advanced or metastatic) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (locally advanced or metastatic) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (locally advanced or metastatic) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Locally Advanced or Metastatic Breast Cancer
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Colorectal Cancer (Locally Advanced or Metastatic)
- Liver Cancer (Locally Advanced or Metastatic)
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.